Bausch Health Companies (TSE:BHC – Get Free Report) declared that its board has approved a stock repurchase plan on Wednesday, October 28th, RTT News reports. The company plans to buy back C$70 million in outstanding shares. This repurchase authorization permits the company to buy up to 1.9% of its shares through open market purchases. Stock repurchase plans are often a sign that the company’s board of directors believes its stock is undervalued.
Analyst Ratings Changes
Separately, Jefferies Financial Group raised Bausch Health Companies to a “hold” rating in a report on Wednesday, July 22nd. Three analysts have rated the stock with a Hold rating. According to data from MarketBeat.com, Bausch Health Companies presently has a consensus rating of “Hold”.
Get Our Latest Stock Analysis on Bausch Health Companies
Bausch Health Companies Stock Up 28.3%
Bausch Health Companies (TSE:BHC – Get Free Report) last posted its earnings results on Wednesday, October 28th. The company reported C$2.52 earnings per share (EPS) for the quarter. The firm had revenue of C$4.19 billion for the quarter. Bausch Health Companies had a positive return on equity of 57.67% and a negative net margin of 7.43%. On average, analysts predict that Bausch Health Companies will post 5.55 earnings per share for the current year.
Bausch Health Companies News Roundup
Here are the key news stories impacting Bausch Health Companies this week:
- Positive Sentiment: Q3 earnings beat expectations: Bausch Health reported quarterly revenue of approximately C$4.19 billion and EPS of C$2.52, while profit increased year over year. The results helped drive the stock higher as investors focused on improved operating performance. Bausch Health Companies Inc. Q3 Profit Climbs
- Positive Sentiment: Revenue outlook raised: Management signaled 2026 revenue of approximately $5.525 billion to $5.625 billion, supporting investor confidence that the company’s business momentum is improving. Bausch Health signals 2026 revenue outlook
- Positive Sentiment: Share buyback announced: The board authorized a repurchase of up to C$70 million of shares, or roughly 1.9% of outstanding stock. Buybacks can support per-share earnings and signal that management believes the shares are undervalued. Bausch Health share buyback report
- Positive Sentiment: Analyst price target increased: Jefferies raised its BHC price target to $8, providing additional support for the bullish reaction to the earnings release. Jefferies raises Bausch Health price target
- Negative Sentiment: Fourth-quarter Xifaxan headwinds: Management cautioned that pressure on Xifaxan could weigh on near-term results, tempering the otherwise positive earnings and outlook news. Bausch Health Q3 earnings call transcript
Bausch Health Companies Company Profile
Bausch Health Companies Inc (NYSE:BHC)(TSX:BHC) is a global diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors.
Further Reading
- Five stocks we like better than Bausch Health Companies
- Phillips 66 Posts Strong Earnings But the Stock Doesn’t Care
- NXP Semiconductors Falls After Strong Earnings—Is the Sell-Off Overdone?
- GE Vernova’s Reservations Are Turning Into Real Orders—But the Market Still Wants More.
- Where’s the Beef? Trian-Led Buyout Proposal Values Wendy’s at $1.4B, But Is It Enough?
Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.
